CAVERJECT Drug Patent Profile

When do Caverject patents expire, and when can generic versions of Caverject launch?

Caverject is a drug marketed by Pfizer and is included in three NDAs.

The generic ingredient in CAVERJECT is alprostadil. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alprostadil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Caverject

A generic version of CAVERJECT was approved as alprostadil by HIKMA on January 20^th, 1998.

Summary for CAVERJECT

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	105
Clinical Trials:	1
Patent Applications:	4,154
Drug Prices:	Drug price information for CAVERJECT
What excipients (inactive ingredients) are in CAVERJECT?	CAVERJECT excipients list
DailyMed Link:	CAVERJECT at DailyMed

See drug prices for CAVERJECT

Recent Clinical Trials for CAVERJECT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
City of Hope Medical Center	Phase 3

See all CAVERJECT clinical trials

Pharmacology for CAVERJECT

Drug Class	Prostaglandin Analog Prostaglandin E1 Agonist
Mechanism of Action	Prostaglandin Receptor Agonists
Physiological Effect	Genitourinary Arterial Vasodilation Venous Vasodilation

US Patents and Regulatory Information for CAVERJECT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-003	Jun 27, 1996		DISCN	Yes	No
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-004	May 19, 1997	AP	RX	Yes	Yes
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020755-002	Oct 1, 1997		DISCN	No	No
Pfizer	CAVERJECT IMPULSE	alprostadil	INJECTABLE;INJECTION	021212-001	Jun 11, 2002		RX	No	No
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020755-001	Oct 31, 1997		DISCN	No	No
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-001	Jul 6, 1995	AP	RX	Yes	No
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020755-003	Oct 1, 1997		DISCN	No	No

Expired US Patents for CAVERJECT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-003	Jun 27, 1996
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-002	Jul 6, 1995
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-002	Jul 6, 1995
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-001	Jul 6, 1995
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-001	Jul 6, 1995
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-004	May 19, 1997

International Patents for CAVERJECT

See the table below for patents covering CAVERJECT around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	725642
New Zealand	273752	STABILISED PROSTAGLANDIN E1 LYOPHILISATE USING TERTIARY BUTANOL AND LACTOSE CARRIERS
Norway	961718
European Patent Office	0725642	PROSTAGLANDINE E 1 STABILISEE (STABILIZED PROSTAGLANDIN E 1)
China	1060042
Finland	116270
Austria	187071

CAVERJECT Market Analysis and Financial Projection Experimental

Erectile Dysfunction Drugs Market: Understanding the Dynamics and Financial Trajectory

Introduction

The global erectile dysfunction (ED) drugs market is experiencing significant growth, driven by various factors including advancements in treatments, increasing awareness, and changing societal attitudes. While the market encompasses a range of drugs, this article will focus on the dynamics and financial trajectory of the market, with a particular emphasis on drugs like CAVERJECT, although specific financial data for CAVERJECT is not provided in the sources.

Market Size and Growth

The global erectile dysfunction drugs market is projected to grow substantially over the next decade. By 2032, the market is anticipated to reach around USD 6.1 billion, up from USD 3.2 billion in 2022, with a compound annual growth rate (CAGR) of 6.8% from 2023 to 2032[1].

Key Drivers of Market Growth

Increasing Prevalence of ED

Erectile dysfunction is a common condition, especially among older men. Approximately half of American men between 40 and 70 years old are affected by ED, with the prevalence increasing with age[1].

Lifestyle Factors

Poor lifestyles, including obesity, diabetes, and heart disease, contribute significantly to the rise in ED cases. Stressful lives, particularly in developing countries, lead to increased consumption of unhealthy foods and substances like alcohol and tobacco, further exacerbating the problem[1].

Advances in Treatments

Significant advancements in ED treatments are a major driver of market growth. Innovations such as new drug delivery methods (e.g., creams and pellets) and ongoing clinical trials for more effective treatments are expanding the market[2].

Increased Awareness and Social Acceptance

Educational campaigns and health initiatives aimed at destigmatizing ED have led to a growing openness in societal attitudes towards discussing sexual health. This increased awareness is driving more men to seek medical help, thereby boosting the market[2].

Regional Analysis

North America

North America dominates the ED drugs market, accounting for 51.7% of the total revenue in 2022. This is due to the high prevalence of ED in the region, a strong healthcare infrastructure, and the approval of new treatments[1].

Asia Pacific

The Asia Pacific region is expected to experience rapid growth during the forecast period, driven by the introduction of new products and increasing investments in healthcare infrastructure[1].

Distribution Channels

Retail Pharmacies

Retail pharmacies hold the largest revenue share of the ED drugs market, accounting for 46% of the market. This dominance is due to the ease of access and the trust consumers have in traditional pharmacy channels[1].

Competitive Landscape

The ED drugs market is highly competitive, with several key players innovating their drug portfolios and expanding their market presence through strategic marketing and educational initiatives. For example, Palatin Technologies is conducting clinical studies to evaluate the efficacy of bremelanotide (BMT) in treating ED in patients who do not respond to standard PDE5 inhibitors like Viagra, Cialis, and Levitra[2].

Drug Type Insights

PDE5 Inhibitors

Drugs like Viagra (sildenafil citrate) are the most popular, holding a 58% revenue share of the ED drugs market. These drugs are preferred due to their long duration of action and lower side effects compared to other treatments[1].

Financial Trajectory

Market Value

The global ED drugs market is expected to grow from USD 3.2 billion in 2022 to USD 6.1 billion by 2032, with a CAGR of 6.8% during the forecast period[1].

Revenue Forecast

Another forecast suggests the market will reach USD 5.04 billion by 2032, growing at a CAGR of 8.3% from 2023 to 2032[4].

Impact of COVID-19

The COVID-19 pandemic has positively affected the ED drugs market. The pandemic has led to an increase in underlying conditions that can cause ED, with the risk of developing ED being almost six times higher in COVID-19 patients[1].

Innovations and Pipeline Drugs

The market is driven by continuous innovations and the development of new treatments. For instance, the evaluation of bremelanotide (BMT) co-administered with a PDE5i is a significant development aimed at treating ED in patients who do not respond to standard treatments[2].

Key Takeaways

• The global ED drugs market is expected to reach USD 6.1 billion by 2032, growing at a CAGR of 6.8% from 2023 to 2032.
• North America dominates the market, with retail pharmacies holding the largest revenue share.
• Advances in treatments and increasing awareness are key drivers of market growth.
• The COVID-19 pandemic has contributed to the market's growth due to increased underlying conditions.

FAQs

What is the projected market size of the erectile dysfunction drugs market by 2032?

The global erectile dysfunction drugs market is anticipated to reach around USD 6.1 billion by 2032[1].

What is the CAGR of the erectile dysfunction drugs market from 2023 to 2032?

The market is expected to grow at a CAGR of 6.8% from 2023 to 2032[1].

Which region dominates the erectile dysfunction drugs market?

North America dominates the market, accounting for 51.7% of the total revenue in 2022[1].

What are the key drivers of the erectile dysfunction drugs market?

Key drivers include the increasing prevalence of ED, lifestyle factors, advances in treatments, and increased awareness and social acceptance[1][2].

How has the COVID-19 pandemic affected the erectile dysfunction drugs market?

The pandemic has positively affected the market by increasing the risk of developing ED, with the risk being almost six times higher in COVID-19 patients[1].

Sources

1. GlobeNewswire: "Erectile Dysfunction Drugs Market Value to Reach USD 6.1 bn by 2032 - Market.us Study"[1]
2. BioSpace: "Erectile Dysfunction Market to Reach USD 3.9 Billion by 2034 Driven by Product Innovations and Expanding Treatment Awareness"[2]
3. NBER: "The Economics of Drug Development: Pricing and Innovation in a Changing Market"[3]
4. Growth Plus Reports: "Erectile Dysfunction Market 2032 - $5.04 billion Revenue Forecast"[4]